Market Inference Brief — NEO Stock

Small-cap Healthcare company NeoGenomics has logged a 2.5% change today on a trading volume of 282,898. The average volume for the stock is 1,271,963.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. Based in Fort Myers, United States the company has 2,000 full time employees and a market cap of $1,420,908,800.

The company is now trading -28.71% away from its average analyst target price of $15.78 per share. The 9 analysts following the stock have set target prices ranging from $10 to $26, and on average give NeoGenomics a rating of buy.

Over the last year, NEO shares have gone down by -53.1%, which represents a difference of -40.4% when compared to the S&P 500. The stock's 52 week high is $24.46 per share and its 52 week low is $6. With its gross margins declining an average -10.4% over the last four years, NeoGenomics may not have a strong enough business to reverse this trend.

Date Reported Revenue ($ MM) Cost of Revenue ($ MM) Gross Margins (%) YoY Growth (%)
2021-12-31 484 297 38.62 -7.67
2020-12-31 444 259 41.83 -13.13
2019-12-31 409 212 48.15 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.